 | This article contains promotional content. (November 2023) |
| Abbreviation | CERN |
|---|---|
| Formation | 2006 |
| Type | Nonprofit |
| Purpose | Develop new treatments for Ependymoma |
| Headquarters | Dayton, Ohio, USA |
Founder | Mark Gilbert, M.D. |
| Website | www |
The Collaborative Ependymoma Research Network (CERN) Foundation is a nonprofit organization composed of scientists and adult and pediatric cancer researchers who work together to develop new treatments for ependymoma, a type of primary brain or spinal cord tumor that occurs in both children and adults, and improve the outcomes and care of patients.[1] The organization is headquartered in Dayton, Ohio, USA.[2]
The CERN Foundation’s research is based on a model that includes preclinical evaluation of new and FDA-approved drugs in laboratory models of ependymoma. The drugs are tested in clinical trials involving both pediatric and adult cancer centers from within the CERN network. The CERN Foundation’s research has been used to design better treatment plans for patients with ependymoma.[3]
- ^ "MD Anderson Cancer Center, Research", 2012-10-08
- ^ "About CERN", 2012-09-06
- ^ Armstrong, TS; Vera-Bolanos, E; Nebiyou Bekele, B; Aldape, K; Gilbert, MR, “Adult ependymal tumors: prognosis and the M.D. Anderson Cancer Center experience”, “Neuro-Oncology”, August 2010